Vericel Corporation (NASDAQ:VCEL - Get Free Report) insider Jonathan Mark Hopper sold 3,472 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $121,520.00. Following the completion of the transaction, the insider owned 75,556 shares in the company, valued at approximately $2,644,460. This trade represents a 4.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vericel Price Performance
Shares of NASDAQ VCEL opened at $34.08 on Tuesday. The stock's fifty day moving average price is $34.60 and its two-hundred day moving average price is $35.83. Vericel Corporation has a one year low of $28.95 and a one year high of $45.97. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 109.94 and a beta of 1.20.
Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, meeting analysts' consensus estimates of $0.45. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The firm had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. During the same period in the prior year, the firm posted $0.38 EPS. The company's revenue for the quarter was up 23.3% on a year-over-year basis. On average, equities analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.
Analyst Ratings Changes
VCEL has been the topic of a number of research reports. Truist Financial decreased their price objective on Vericel from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Thursday, December 18th. Leerink Partners restated an "outperform" rating and set a $46.00 target price on shares of Vericel in a research report on Tuesday, March 10th. HC Wainwright increased their target price on shares of Vericel from $60.00 to $64.00 and gave the stock a "buy" rating in a research report on Friday, February 27th. Weiss Ratings restated a "hold (c-)" rating on shares of Vericel in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Vericel from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $56.00.
Read Our Latest Analysis on Vericel
Institutional Trading of Vericel
Several large investors have recently bought and sold shares of VCEL. AQR Capital Management LLC acquired a new stake in Vericel in the first quarter valued at about $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Vericel by 6.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company's stock valued at $1,403,000 after buying an additional 1,847 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Vericel by 13.6% in the first quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company's stock valued at $16,576,000 after buying an additional 44,333 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Vericel by 9.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company's stock valued at $5,490,000 after buying an additional 10,191 shares in the last quarter. Finally, WINTON GROUP Ltd boosted its stake in Vericel by 30.8% in the second quarter. WINTON GROUP Ltd now owns 17,036 shares of the biotechnology company's stock valued at $725,000 after buying an additional 4,015 shares in the last quarter.
About Vericel
(
Get Free Report)
Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company's expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.
Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
